This is the authors' abstract. We don't add key points for this paper.
Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20% of patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Broccoli et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: